Clinical Trials
25 trialsNCT02296918 2025-12-19
Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL
Acerta Pharma BV
Phase 1 Completed
NCT05364424 2025-12-01
A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma
Hoffmann-La Roche
Phase 1 Completed
NCT03039114 2025-08-21
Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Incyte Corporation
Phase 1 Completed
NCT04826003 2025-07-14
Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment
Hoffmann-La Roche
Phase 1 Completed
NCT04578600 2025-04-24
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
University of California, Davis
Phase 1 Completed
NCT04599634 2025-02-04
Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03467373 2025-01-17
A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL
Hoffmann-La Roche
Phase 1 Completed
NCT02569476 2024-10-26
BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies
BeiGene
Phase 1 Completed
NCT04434196 2024-07-25
A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Celgene
Phase 1 Completed
NCT04313608 2024-03-25
A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 1 Completed
NCT04657302 2024-01-19
A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 1 Completed
NCT02417285 2023-10-23
A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.
Celgene
Phase 1 Completed
NCT04551352 2022-10-03
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
Hoffmann-La Roche
Phase 1 Completed
NCT03113695 2022-07-05
Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome
University of California, San Diego
Phase 1 Completed
NCT02877550 2022-06-10
Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients
Swiss Cancer Institute
Phase 1 Completed
NCT01671904 2020-10-14
A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Genentech, Inc.
Phase 1 Completed
NCT02174172 2020-05-12
A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT02324257 2020-04-17
A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT02220842 2020-01-27
A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Hoffmann-La Roche
Phase 1 Completed
NCT01685892 2020-01-10
A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia
Genentech, Inc.
Phase 1 Completed
NCT02100852 2019-10-02
TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)
TG Therapeutics, Inc.
Phase 1 Completed
NCT02453087 2019-08-29
A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Hoffmann-La Roche
Phase 1 Completed
NCT01300247 2017-02-02
A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON)
Genentech, Inc.
Phase 1 Completed
NCT00825149 2016-11-04
GAUDI
Hoffmann-La Roche
Phase 1 Completed
NCT01680991 2016-04-25
A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease
Hoffmann-La Roche
Phase 1 Completed